Sign in

    Tess Romero

    Biotechnology Equity Analyst at JPMorgan Chase & Co.

    Tessa Romero is a Biotechnology Equity Analyst at JPMorgan Chase & Co., specializing in equity research within the biotechnology sector and based in New York City. She covers companies such as Biohaven, providing investment recommendations and target price updates, with recent performance reflected by coverage changes and price target adjustments for leading biotech firms. Romero began her current role at JPMorgan Chase after serving as an Equity Research Associate, and she has held analyst positions for an average tenure of around 1 year and 8 months per company throughout her career. She operates in the investment management industry and is recognized for her analytical expertise in biotechnology equities, though specific securities licenses or FINRA registrations are not publicly listed.

    Tess Romero's questions to Neumora Therapeutics (NMRA) leadership

    Tess Romero's questions to Neumora Therapeutics (NMRA) leadership • Q2 2025

    Question

    An analyst on behalf of Tess Romero asked about the synergies between Neumora's neuroscience pipeline and the new focus on obesity, the rationale for entering the indication, and for clarification on what R&D initiatives are included in the current cash runway guidance.

    Answer

    Joshua Pinto, President, addressed the questions. He stated that obesity fits squarely within Neumora's mandate to tackle large population health disorders driven by central mechanisms, leveraging the team's expertise in developing brain-penetrant molecules. Regarding the cash runway, he confirmed the balance of $217 million provides runway into 2027 and fully funds all critical programs, including NMRA-215, through their currently guided clinical milestones. This funding covers the six potential clinical catalysts expected over the next 18 months.

    Ask Fintool Equity Research AI

    Tess Romero's questions to ACADIA PHARMACEUTICALS (ACAD) leadership

    Tess Romero's questions to ACADIA PHARMACEUTICALS (ACAD) leadership • Q3 2024

    Question

    An analyst on behalf of Tess Romero of JPMorgan Chase & Co. asked for clarification on the statement that the Daybue launch has reached a 'steady state of new patient flow,' inquiring if this means steady net adds and what the strategy is to accelerate new patient starts.

    Answer

    CEO Catherine Owen Adams explained that after a strong initial launch burst, new patient additions have plateaued, which is common for rare disease launches. To re-accelerate growth, the strategy focuses on three areas: 1) better communicating the drug's efficacy by translating clinical scales into real-world benefits, 2) improving management of the early patient journey to enhance persistence, and 3) increasing penetration outside of Centers of Excellence (COEs), where 70% of patients are treated.

    Ask Fintool Equity Research AI